Clinical Commander

Back to dossier
cardio.atrial_flutter.with-pe.v1PRODUCTION
cardio.atrial_flutter.with-pe.v1

Atrial flutter with concurrent acute pulmonary embolism

cardiologyacuteadult
Hard-required inputs
0 / 14
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Atrial flutter + acute pulmonary embolism — composite event with two parallel decisions: (1) PE severity triage (massive vs sub-massive vs low-risk) drives reperfusion (systemic tPA / CDT-EKOS / AC alone); (2) AFL rate control with RV-protective dosing (BB/diltiazem cautious — RV failure intolerant) + dual AC indication (CHA2DS2-VASc + PE → DOAC full dose). ESC 2019 PE (PMID 31504429) + ACC/AHA 2024 AF (PMID 38753446)

Inputs
2
Actions
0
Advance rule
Set
Advance when

composite AFL + PE confirmed

Patient inputs (16)

CHA2DS2-VASc + PE severity scoring (PESI) + frailty/bleed-risk for thrombolysis decision

AFL RVR + PE-induced sinus tachy combine to drive demand ischemia + RV failure; HR target 80–110

CT-PA gold standard for PE diagnosis; clot burden + RV/LV ratio + central vs peripheral location drives severity tiering — ESC 2019 (PMID 31504429)

Bedside echo for RV strain (McConnell sign, septal flattening, dilated IVC, TAPSE <16); drives sub-massive PE classification + thrombolysis decision — ESC 2019

Confirm AFL morphology + rate; look for RV strain pattern (S1Q3T3, RBBB, anterior T-wave inversions); rule out STEMI mimics

Troponin elevation in PE indicates RV strain/microinfarction → sub-massive classification; persistent elevation portends worse outcomes — ESC 2019

NT-proBNP rise reflects RV pressure overload; elevation supports sub-massive PE; combined with troponin for risk tiering — ESC 2019

eGFR for DOAC dose adjustment (PE treatment dose) + contrast for CT-PA + IV contrast risk

Baseline coags pre-thrombolysis screening (tPA contraindicated if plt <100k or INR >1.7) + AC initiation

SBP <90 with PE = massive PE (Class I thrombolysis); SBP <90 with AFL RVR = unstable arrhythmia → DCCV; both states warrant ICU

Hypoxemia from V/Q mismatch in PE; supplemental O2 if SpO2 <90%; HFNC or BiPAP for respiratory failure

Lactate elevation indicates tissue hypoperfusion from RV failure / shock; >2 mmol/L raises concern for massive PE

CHA2DS2-VASc for AFL stroke risk; combined with PE indication → indefinite full-dose AC if AFL persistent

HAS-BLED + PE-thrombolysis bleed contraindications (recent surgery, GI bleed, prior ICH, current AC)

Patent foramen ovale with right-to-left shunt → paradoxical embolism risk (stroke despite PE); bubble study on TTE

D-dimer often elevated in AFL alone (low specificity); use to support clinical pre-test probability per Wells/Geneva but CT-PA is definitive given pre-test probability already raised

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmassive_pe_with_hemodynamic_instability
    Massive PE with SBP <90 + RV failure on echo (McConnell sign, septal flattening, dilated IVC, TAPSE <16) + lactate ≥2 — Class I systemic thrombolysis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrv_failure_progression_during_aflutter_rate_control
    AFL rate control attempted with BB or non-DHP CCB precipitates RV failure progression (worsening hypotension, rising lactate, declining TAPSE) — iatrogenic decompensation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningparadoxical_embolism_via_pfo_with_stroke
    New focal neuro deficit during PE workup or treatment + bubble study positive for PFO with right-to-left shunt — paradoxical embolism causing stroke
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninganticoagulation_related_major_bleed_in_dual_indication
    Major bleeding (intracranial, GI requiring transfusion, retroperitoneal, hemodynamic compromise) on AC for dual AFL+PE indication
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcardiac_arrest_from_pe_during_aflutter_workup
    PEA arrest during AFL workup with high suspicion or confirmed PE — high-mortality presentation
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Atrial flutter + acute PE — PE-severity-tiered reperfusion + RV-protective rate control + dual-indication AC pathway — ESC 2019 PE (PMID 31504429) + ACC/AHA 2024 AF (PMID 38753446) + PEITHO (PMID 24716683)
axis: aflutter_with_pe_severity_tiered_pathway
Selected axis "Atrial flutter + acute PE — PE-severity-tiered reperfusion + RV-protective rate control + dual-indication AC pathway — ESC 2019 PE (PMID 31504429) + ACC/AHA 2024 AF (PMID 38753446) + PEITHO (PMID 24716683)" by default fallback (first axis)
  • alteplase
    first line
    tissue_plasminogen_activator
    100 mg IV over 2 h (or 0.5 mg/kg over 15 min if PE-related cardiac arrest); UFH bridge 60 U/kg bolus then 12 U/kg/h to PTT 1.5–2× control • IV • one-time infusion
    triggers: massive_pe_with_sbp_below_90, pe_with_cardiac_arrest, no_thrombolysis_contraindication
    Massive PE Class I (ESC 2019 PMID 31504429); reduces in-hospital mortality; major bleed ~10%; intracranial hemorrhage ~2%
    rxcui 8410
  • tenecteplase
    first line
    tissue_plasminogen_activator
    30–50 mg IV bolus weight-based (60 kg <30 mg, 60–70 kg 35 mg, 70–80 kg 40 mg, 80–90 kg 45 mg, ≥90 kg 50 mg); UFH bridge • IV • single bolus
    triggers: massive_pe_alternative_to_alteplase, sub_massive_pe_per_PEITHO_with_low_bleed_risk_under_75
    PEITHO (Meyer NEJM 2014 PMID 24716683) — single bolus convenience; sub-massive PE Class IIa risk-benefit individualized given bleed risk
    rxcui 259280
  • unfractionated_heparin
    first line
    heparin
    60 U/kg IV bolus (max 5000 U) → 12 U/kg/h infusion (max 1000 U/h); titrate to PTT 1.5–2× control or anti-Xa 0.3–0.7 • IV • bolus + continuous
    triggers: massive_or_sub_massive_pe_initial, pre_thrombolysis_or_CDT_bridge, pre_DOAC_initiation
    Initial AC for massive/sub-massive PE; preferred over LMWH given thrombolysis option + reversibility — ESC 2019 (PMID 31504429)
    rxcui 5224
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC q12h (1.5 mg/kg q24h alternative); 1 mg/kg q24h if CrCl 15–30 • SC • BID
    triggers: low_or_intermediate_risk_pe_no_thrombolysis_planned, malignancy_with_PE
    LMWH preferred for low/intermediate-risk PE without thrombolysis plan — ESC 2019; weight-based monitoring not routinely needed
    rxcui 67108
  • apixaban
    first line
    DOAC_factor_Xa
    10 mg BID × 7 days → 5 mg BID maintenance (covers both AFL stroke prevention + PE treatment at single dose; 2.5 mg BID for AFL component if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5 — but maintain full 5 mg BID for first 6 mo to cover PE) • PO • BID
    triggers: low_risk_or_post_acute_PE, AFL_with_CHA2DS2VASc_>=2, oral_AC_initiation
    AMPLIFY (Agnelli NEJM 2013 PMID 23808982) for VTE; ARISTOTLE (PMID 21870978) for AF; single dose covers both indications
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    15 mg BID × 21 days → 20 mg daily with food (15 mg daily if CrCl 15–50) • PO • BID then daily
    triggers: low_risk_or_post_acute_PE, AFL_with_CHA2DS2VASc_>=2, apixaban_unavailable
    EINSTEIN-PE (Buller NEJM 2012 PMID 22449293) for VTE; ROCKET-AF (PMID 21830957) for AF; loading-dose pattern covers acute PE phase
    rxcui 1114195
  • dabigatran
    second line
    DOAC_direct_thrombin
    150 mg BID after 5–10 days of parenteral AC (UFH or LMWH); avoid CrCl <30 • PO • BID
    triggers: low_risk_or_post_acute_PE_after_parenteral_lead_in, idarucizumab_reversal_preference
    RE-COVER (Schulman NEJM 2009 PMID 19966341) for VTE; requires 5–10 d parenteral lead-in (not direct-start like apixaban/rivaroxaban)
    rxcui 1037045
  • edoxaban
    second line
    DOAC_factor_Xa
    60 mg daily after 5–10 days of parenteral AC (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor) • PO • once daily
    triggers: low_risk_or_post_acute_PE_after_parenteral_lead_in
    HOKUSAI-VTE (Buller NEJM 2013 PMID 23991658); requires parenteral lead-in
    rxcui 1599538
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3; bridge with UFH/LMWH until therapeutic ×24h • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, antiphospholipid_syndrome_triple_positive, DOAC_contraindicated, severe_renal_failure_CrCl_<15
    Mechanical valve, severe MS, triple-positive APS, severe CKD → warfarin only — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289
  • metoprolol_tartrate
    comorbidity specific
    beta_blocker
    REDUCED DOSE: 2.5 mg IV initially (NOT full 5 mg q5min × 3); reassess RV/SBP/lactate before each subsequent dose; PO 12.5 mg BID start, titrate cautiously • IV/PO • reduced cadence; per RV tolerance
    triggers: aflutter_RVR_with_preserved_RV_function_and_SBP_>100, no_signs_of_RV_failure_progression
    AVN slowing for AFL but RV-failure risk in PE — start LOW dose, monitor SBP + lactate + RV echo; AVOID if SBP <100 or echo shows RV strain progression — ESC 2019 (PMID 31504429); ACC/AHA 2024 (PMID 38753446)
    rxcui 203191
  • diltiazem
    comorbidity specific
    non_DHP_CCB
    REDUCED DOSE: 0.15 mg/kg IV (NOT full 0.25 mg/kg) over 2 min; infusion 5 mg/h start (NOT 10–15); avoid if SBP <100 or RV failure progression • IV/PO • reduced cadence
    triggers: BB_intolerant_with_AFL_RVR, preserved_RV_function_and_SBP_>100
    AVN slowing alternative; AVOID full doses given negative inotropic effect on already-strained RV; AVOID in HFrEF; ESC 2019 (PMID 31504429)
    rxcui 3443

outpatient playbook — drug actions (2)

  1. 1. continue DOAC lifelong if AFL persistent
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria • PO • BID
    trigger: Lifelong stroke prevention + PE secondary prevention
    ACC/AHA 2024 + ESC 2019
  2. 2. wean rate control if successful CTI ablation
    rxcui 866427
    taper metoprolol over 4–8 weeks if no recurrence at 3 mo • PO • taper
    trigger: Successful ablation + no recurrence
    ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Atrial flutter on monitor + acute dyspnea / pleuritic chest pain / unexplained tachycardia → CT-PA to evaluate concurrent PE; CT-PA confirmed PE in patient with atrial flutter on telemetry — composite event; New AFL on ECG with RV strain pattern (S1Q3T3, T-wave inversions V1-V4, RBBB) → STAT CT-PA.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter with concurrent acute pulmonary embolism** (cardio.atrial_flutter.with-pe.v1).
Phenotype framing: AFL+PE vs AFL alone with sinus tachycardia mimicking PE; PE alone with secondary AF/flutter; ACS with arrhythmia (acs_pathway routing); pneumonia/COPD exacerbation with concurrent AFL
Scope: Atrial flutter + acute pulmonary embolism — composite event with two parallel decisions: (1) PE severity triage (massive vs sub-massive vs low-risk) drives reperfusion (systemic tPA / CDT-EKOS / AC alone); (2) AFL rate control with RV-protective dosing (BB/diltiazem cautious — RV failure intolerant) + dual AC indication (CHA2DS2-VASc + PE → DOAC full dose). ESC 2019 PE (PMID 31504429) + ACC/AHA 2024 AF (PMID 38753446)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Atrial flutter + acute PE — PE-severity-tiered reperfusion + RV-protective rate control + dual-indication AC pathway — ESC 2019 PE (PMID 31504429) + ACC/AHA 2024 AF (PMID 38753446) + PEITHO (PMID 24716683)**.
1. alteplase 100 mg IV over 2 h (or 0.5 mg/kg over 15 min if PE-related cardiac arrest); UFH bridge 60 U/kg bolus then 12 U/kg/h to PTT 1.5–2× control IV one-time infusion (tissue_plasminogen_activator, first line) — Massive PE Class I (ESC 2019 PMID 31504429); reduces in-hospital mortality; major bleed ~10%; intracranial hemorrhage ~2%
2. tenecteplase 30–50 mg IV bolus weight-based (60 kg <30 mg, 60–70 kg 35 mg, 70–80 kg 40 mg, 80–90 kg 45 mg, ≥90 kg 50 mg); UFH bridge IV single bolus (tissue_plasminogen_activator, first line) — PEITHO (Meyer NEJM 2014 PMID 24716683) — single bolus convenience; sub-massive PE Class IIa risk-benefit individualized given bleed risk
3. unfractionated_heparin 60 U/kg IV bolus (max 5000 U) → 12 U/kg/h infusion (max 1000 U/h); titrate to PTT 1.5–2× control or anti-Xa 0.3–0.7 IV bolus + continuous (heparin, first line) — Initial AC for massive/sub-massive PE; preferred over LMWH given thrombolysis option + reversibility — ESC 2019 (PMID 31504429)
4. enoxaparin 1 mg/kg SC q12h (1.5 mg/kg q24h alternative); 1 mg/kg q24h if CrCl 15–30 SC BID (lmwh, first line) — LMWH preferred for low/intermediate-risk PE without thrombolysis plan — ESC 2019; weight-based monitoring not routinely needed
5. apixaban 10 mg BID × 7 days → 5 mg BID maintenance (covers both AFL stroke prevention + PE treatment at single dose; 2.5 mg BID for AFL component if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5 — but maintain full 5 mg BID for first 6 mo to cover PE) PO BID (DOAC_factor_Xa, first line) — AMPLIFY (Agnelli NEJM 2013 PMID 23808982) for VTE; ARISTOTLE (PMID 21870978) for AF; single dose covers both indications
6. rivaroxaban 15 mg BID × 21 days → 20 mg daily with food (15 mg daily if CrCl 15–50) PO BID then daily (DOAC_factor_Xa, first line) — EINSTEIN-PE (Buller NEJM 2012 PMID 22449293) for VTE; ROCKET-AF (PMID 21830957) for AF; loading-dose pattern covers acute PE phase
7. dabigatran 150 mg BID after 5–10 days of parenteral AC (UFH or LMWH); avoid CrCl <30 PO BID (DOAC_direct_thrombin, second line) — RE-COVER (Schulman NEJM 2009 PMID 19966341) for VTE; requires 5–10 d parenteral lead-in (not direct-start like apixaban/rivaroxaban)
8. edoxaban 60 mg daily after 5–10 days of parenteral AC (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor) PO once daily (DOAC_factor_Xa, second line) — HOKUSAI-VTE (Buller NEJM 2013 PMID 23991658); requires parenteral lead-in
9. warfarin 5 mg daily; INR target 2–3; bridge with UFH/LMWH until therapeutic ×24h PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve, severe MS, triple-positive APS, severe CKD → warfarin only — ACC/AHA 2024 (PMID 38753446)
10. metoprolol_tartrate REDUCED DOSE: 2.5 mg IV initially (NOT full 5 mg q5min × 3); reassess RV/SBP/lactate before each subsequent dose; PO 12.5 mg BID start, titrate cautiously IV/PO reduced cadence; per RV tolerance (beta_blocker, comorbidity specific) — AVN slowing for AFL but RV-failure risk in PE — start LOW dose, monitor SBP + lactate + RV echo; AVOID if SBP <100 or echo shows RV strain progression — ESC 2019 (PMID 31504429); ACC/AHA 2024 (PMID 38753446)
11. diltiazem REDUCED DOSE: 0.15 mg/kg IV (NOT full 0.25 mg/kg) over 2 min; infusion 5 mg/h start (NOT 10–15); avoid if SBP <100 or RV failure progression IV/PO reduced cadence (non_DHP_CCB, comorbidity specific) — AVN slowing alternative; AVOID full doses given negative inotropic effect on already-strained RV; AVOID in HFrEF; ESC 2019 (PMID 31504429)

Setting playbook (outpatient) — Long-term AFL management + secondary PE prevention; lifelong DOAC if AFL persistent; CTI ablation for typical AFL; CTEPH surveillance; routing to typical/atypical AFL variants per ECG morphology — ACC/AHA 2024 + ESC 2019
12. continue DOAC lifelong if AFL persistent apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria PO BID — Lifelong stroke prevention + PE secondary prevention (ACC/AHA 2024 + ESC 2019)
13. wean rate control if successful CTI ablation taper metoprolol over 4–8 weeks if no recurrence at 3 mo PO taper — Successful ablation + no recurrence (ACC/AHA 2024)

Non-pharmacologic actions:
- Cardiac + pulmonary rehab maintenance
- Lifestyle: BP, weight, alcohol, OSA, exercise, smoking cessation
- LAA occlusion (Watchman) consideration if AC contraindicated long-term — ACC/AHA 2024
- Pulmonary endarterectomy or balloon pulmonary angioplasty consideration if CTEPH (specialist center)

AVOID / contraindication checks:
- Systemic thrombolysis contraindicated if active bleeding recent surgery 2wk prior ICH stroke 3mo — ESC 2019 (PMID 31504429)
- Full dose BB or non DHP CCB CAUTION with RV failure from PE — ESC 2019
- Digoxin AVOID with acute PE no evidence of benefit and narrow toxicity window
- DOAC renal dose adjustment PE treatment doses different from AF doses
- Warfarin only if mechanical valve or severe MS or triple positive APS — ACC/AHA 2024 (PMID 38753446)
- LMWH preferred for malignancy associated PE then DOAC after 1 mo — ESC 2019
- Dabigatran edoxaban require parenteral lead in 5 to 10 days NOT direct start

Monitoring

Regimen monitoring:
- SpO2 + work of breathing continuous first 24h post thrombolysis — ESC 2019
- BP q15min x 2h post thrombolysis then q1h x 24h for bleed screen — ESC 2019
- PTT q6h during UFH or anti-Xa q12h — standard
- serial troponin + NT-proBNP q12h x 48h for RV strain trend — ESC 2019
- echo at 24h then 48h post thrombolysis for RV function recovery — ESC 2019
- telemetry continuous for AFL + arrhythmia + RV failure progression
- CBC + eGFR q6m on DOAC — ESC 2024
- 3-mo follow-up echo for CTEPH screen — ESC 2019 (PMID 31504429)
- lifelong AC if AFL persistent or unprovoked PE — ACC/AHA 2024 + ESC 2019

Setting (outpatient) monitoring:
- Quarterly clinic + annual TTE
- CBC + eGFR q6m on DOAC
- Holter at 6 + 12 mo post-ablation for recurrence (Calkins 2007 PMID 17572388)

Follow-up plan: Pulmonology + cardiology + EP for AFL ablation candidacy; 3-mo follow-up echo for CTEPH screen (~3% incidence post-PE); thrombophilia workup if unprovoked PE + age <50; lifelong DOAC if AFL persistent or unprovoked PE; CTI ablation for typical AFL; pulmonary rehab
- Close-out criterion: follow-up booked + secondary prevention plan

Monitoring phase: Telemetry continuous for AFL + arrhythmia; serial troponin/NT-proBNP for RV strain trend; daily echo for first 48 h post-thrombolysis; BMP + creatinine for DOAC dose; SpO2 + work of breathing; PE follow-up echo at 3 mo for chronic thromboembolic pulmonary hypertension (CTEPH) screen

Disposition

Current setting: outpatient — Long-term AFL management + secondary PE prevention; lifelong DOAC if AFL persistent; CTI ablation for typical AFL; CTEPH surveillance; routing to typical/atypical AFL variants per ECG morphology — ACC/AHA 2024 + ESC 2019

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 if typical morphology + CTI ablation pathway

Escalation triggers (move to higher acuity):
- Recurrent PE despite AC → re-evaluate, consider IVC filter or agent switch
- Major bleed on AC → hold + reverse + reassess long-term strategy (LAA occlusion candidacy)
- CTEPH progression → pulmonary endarterectomy referral + riociguat
- New AF detected — same AC strategy already in place

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Massive PE with SBP <90 + RV failure on echo (McConnell sign, septal flattening, dilated IVC, TAPSE <16) + lactate ≥2 — Class I systemic thrombolysis
- [LIFE_THREATENING] AFL rate control attempted with BB or non-DHP CCB precipitates RV failure progression (worsening hypotension, rising lactate, declining TAPSE) — iatrogenic decompensation
- [LIFE_THREATENING] New focal neuro deficit during PE workup or treatment + bubble study positive for PFO with right-to-left shunt — paradoxical embolism causing stroke

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2019 Acute PE Guideline (Konstantinides PMID 31504429) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 31504429) [PMID:31504429](https://pubmed.ncbi.nlm.nih.gov/31504429/)
- Cited evidence (PMID 24716683) [PMID:24716683](https://pubmed.ncbi.nlm.nih.gov/24716683/)
- Cited evidence (PMID 23808982) [PMID:23808982](https://pubmed.ncbi.nlm.nih.gov/23808982/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2019 Acute PE Guideline (Konstantinides PMID 31504429) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 31504429) — PMID:31504429
  • Cited evidence (PMID 24716683) — PMID:24716683
  • Cited evidence (PMID 23808982) — PMID:23808982